NCT00019539 2024-03-04
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
8 trialsNCT00020046 2023-10-31
Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00089609 2018-04-20
Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00027664 2013-08-07
Interferon Alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00046826 2013-04-04
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00083005 2012-03-15
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00005966 2009-02-05
Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00001446 2008-03-04
A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed